• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Kaleo plans 2017 U.S. relaunch for EpiPen competitor Auvi-Q

October 26, 2016 By Sarah Faulkner

Kaleo PharmaKaléo Inc. said today that it plans to relaunch its Auvi-Q injector for emergency allergy treatment in the U.S. during the 1st half of 2017, according to Reuters. 

The Richmond, Va.-based company’s device was recalled last year after concerns about the accuracy of delivered dose. Sanofi (NYSE:SNY) made and licensed the Auvi-Q device from Kaléo, but returned rights to the product in February following the recall.

Auvi-Q is similar to Mylan‘s (NSDQ:MYL) EpiPen in that it delivers epinephrine to a patient suffering from a potentially life-threatening allergic reaction. However, instead of a pen-shaped device, Auvi-Q is the length and width of a credit card and is as thick as a small cellphone. It includes a voice prompt system to help patients use the device and has a needle that retracts automatically after the proper dose has been delivered.

Mylan came under fire this year when reports revealed that it raised its list price for a pair of the injectors to $600 from $100 when it acquired the product in 2007.

Amid the widespread criticism from politicians, Mylan pledged to launch a generic EpiPen by the end of 2016, which will sell at a list price of $300, and to broaden its patient assistance program.

Kaléo declined to comment on a list price for the relaunched Auvi-Q to Reuters. “We are working on what is the right price to assure that the ultimate patient co-pay is low,” CEO Spencer Williamson told the news service.

Kaléo also sells a hand-held device, Evzio, that automatically delivers a pre-set dose of naloxone, the drug approved to treat an opioid overdose. Evzio has a list price of $3,750 for 2 active devices and 1 training device.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured Tagged With: Kaleo Inc, Mylan, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS